S&P 500   3,923.68
DOW   31,490.07
QQQ   291.14
S&P 500   3,923.68
DOW   31,490.07
QQQ   291.14
S&P 500   3,923.68
DOW   31,490.07
QQQ   291.14
S&P 500   3,923.68
DOW   31,490.07
QQQ   291.14

Compare Stocks

Enter up to ten stock symbols separated by a comma or space (ex. SYNH,MEDP,EXAS,ICLR,INCY).

Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
SYNH
Syneos Health
$67.47
-5.4%
$76.96
$66.73
$104.18
$6.92B1.79719,368 shs615,004 shs
MEDP
Medpace
$131.45
-5.1%
$150.94
$126.94
$231.00
$4.42B1.53344,654 shs598,528 shs
EXAS
Exact Sciences
$52.00
-3.9%
$63.01
$46.15
$133.99
$9.15B1.232.16 million shs2.55 million shs
ICLR
ICON Public
$203.27
-2.8%
$233.39
$199.01
$313.00
$16.54B0.97614,848 shs622,358 shs
INCY
Incyte
$73.39
-2.8%
$77.41
$61.91
$88.26
$16.26B0.711.66 million shs1.59 million shs

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
SYNH
Syneos Health
-5.41%-1.30%-14.05%-14.98%-20.88%
MEDP
Medpace
-5.06%+0.52%-13.68%-7.60%-18.67%
EXAS
Exact Sciences
-3.90%+7.88%-23.35%-30.45%-46.16%
ICLR
ICON Public
-2.81%-0.77%-16.51%-11.60%-8.59%
INCY
Incyte
-2.81%-0.70%-8.64%+8.20%-10.26%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionCommunity RankDividend StrengthCompany OwnershipEarnings & Valuation
SYNH
Syneos Health
2.22 of 5 Stars
3.44.80.01.71.3
MEDP
Medpace
2.50 of 5 Stars
3.54.40.03.31.3
EXAS
Exact Sciences
2.51 of 5 Stars
4.45.00.02.50.6
ICLR
ICON Public
2.80 of 5 Stars
4.44.40.03.31.9
INCY
Incyte
2.91 of 5 Stars
2.35.00.04.23.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
SYNH
Syneos Health
2.75
Buy$101.0049.70% Upside
MEDP
Medpace
3.00
Buy$182.6338.94% Upside
EXAS
Exact Sciences
2.82
Buy$106.00103.85% Upside
ICLR
ICON Public
2.78
Buy$284.3339.88% Upside
INCY
Incyte
2.50
Buy$87.0918.67% Upside

Current Analyst Ratings

Latest SYNH, MEDP, EXAS, ICLR, and INCY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2022
ICLR
ICON Public
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$285.00
5/3/2022
INCY
Incyte
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price Target$75.00 ➝ $77.00
4/27/2022
EXAS
Exact Sciences
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$100.00 ➝ $81.00
4/27/2022
EXAS
Exact Sciences
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$100.00 ➝ $90.00
4/27/2022
EXAS
Exact Sciences
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$90.00 ➝ $80.00
4/27/2022
EXAS
Exact Sciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$80.00 ➝ $65.00
4/25/2022
SYNH
Syneos Health
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$101.00 ➝ $75.00
4/25/2022
ICLR
ICON Public
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$280.00 ➝ $250.00
4/20/2022
INCY
Incyte
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight$73.00 ➝ $76.00
4/19/2022
EXAS
Exact Sciences
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy$100.00 ➝ $85.00
4/11/2022
SYNH
Syneos Health
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$102.00
(Data available from 5/19/2019 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
SYNH
Syneos Health
$5.21B1.33$6.06 per share11.14$32.91 per share2.05
MEDP
Medpace
$1.14B3.87$5.30 per share24.79$26.51 per share4.96
EXAS
Exact Sciences
$1.77B5.18N/AN/A$19.66 per share2.64
ICLR
ICON Public
$5.48B3.02$11.04 per share18.41$99.11 per share2.05
INCY
Incyte
$2.99B5.44$2.33 per share31.50$17.07 per share4.30

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
SYNH
Syneos Health
$234.83M$2.3129.2112.88N/A4.54%13.33%5.40%8/8/2022 (Estimated)
MEDP
Medpace
$181.85M$5.3624.5220.57N/A16.47%24.17%13.21%7/25/2022 (Estimated)
EXAS
Exact Sciences
-$595.63M-$4.32N/AN/AN/A-40.26%-21.82%-11.23%7/27/2022 (Estimated)
ICLR
ICON Public
$153.18M$2.4981.6316.161.082.58%11.33%5.31%7/20/2022 (Estimated)
INCY
Incyte
$948.58M$4.2017.4719.840.9029.95%12.77%9.68%8/2/2022 (Estimated)

Latest SYNH, MEDP, EXAS, ICLR, and INCY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/3/2022Q1 2022
INCY
Incyte
$0.34$0.40+$0.06$0.63$753.54 million$733.20 million    
4/29/20223/31/2022
SYNH
Syneos Health
$0.95$1.01+$0.06N/A$1.32 billion$1.34 billion    
4/27/2022Q1 2022
ICLR
ICON Public
$2.48$2.60+$0.12$3.84$1.88 billion$1.90 billion    
4/26/2022Q1 2022
EXAS
Exact Sciences
-$1.12-$1.04+$0.08-$1.04$461.86 million$486.57 million      
4/25/20223/31/2022
MEDP
Medpace
$1.26$1.69+$0.43N/A$327.09 million$330.90 million    
2/22/2022Q4 2021
EXAS
Exact Sciences
-$0.91-$1.28-$0.37-$1.28$447.56 million$473.81 million    
2/22/2022Q4 2021
ICLR
ICON Public
$2.40$2.44+$0.04$3.96$1.90 billion$1.89 billion    
(Earnings results data provided by Zacks Investment Research)

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
SYNH
Syneos Health
N/AN/AN/AN/AN/A
MEDP
Medpace
N/AN/AN/AN/AN/A
EXAS
Exact Sciences
N/AN/AN/AN/AN/A
ICLR
ICON Public
N/AN/AN/AN/AN/A
INCY
Incyte
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
SYNH
Syneos Health
0.89
1.09
1.09
MEDP
Medpace
N/A
0.61
0.61
EXAS
Exact Sciences
0.67
2.53
2.29
ICLR
ICON Public
0.63
1.13
1.13
INCY
Incyte
0.01
3.71
3.67

Ownership

Institutional Ownership

CompanyInstitutional Ownership
SYNH
Syneos Health
98.38%
MEDP
Medpace
79.7%
EXAS
Exact Sciences
94.45%
ICLR
ICON Public
89.41%
INCY
Incyte
92.78%

Insider Ownership

CompanyInsider Ownership
SYNH
Syneos Health
0.34%
MEDP
Medpace
20.6%
EXAS
Exact Sciences
1.4%
ICLR
ICON Public
44%
INCY
Incyte
15.8%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
SYNH
Syneos Health
28,000102.58 million102.23 millionOptionable
MEDP
Medpace
4,50033.65 million26.72 millionOptionable
EXAS
Exact Sciences
6,500175.95 million173.48 millionOptionable
ICLR
ICON Public
38,33081.39 million45.58 millionOptionable
INCY
Incyte
2,094221.51 million186.51 millionOptionable

SYNH, MEDP, EXAS, ICLR, and INCY Headlines

SourceHeadline
For Atopic Dermatitis Treatment, an Abundance of Options - Managed Healthcare ExecutiveFor Atopic Dermatitis Treatment, an Abundance of Options - Managed Healthcare Executive
managedhealthcareexecutive.com - May 18 at 9:54 PM
BriaCell Adds Additional Clinical Sites to Broaden Patient Access and Further Boost Enrollment - Yahoo FinanceBriaCell Adds Additional Clinical Sites to Broaden Patient Access and Further Boost Enrollment - Yahoo Finance
finance.yahoo.com - May 18 at 11:51 AM
Incyte Co. (NASDAQ:INCY) Short Interest UpdateIncyte Co. (NASDAQ:INCY) Short Interest Update
marketbeat.com - May 17 at 5:44 AM
Innovent Will Present Clinical Data of IBI110 (anti-LAG-3 monoclonal antibody) and Other Multiple Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - PR NewswireInnovent Will Present Clinical Data of IBI110 (anti-LAG-3 monoclonal antibody) and Other Multiple Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - PR Newswire
prnewswire.com - May 15 at 9:03 PM
Why CTI Biopharma Stock Is Surging Today - NasdaqWhy CTI Biopharma Stock Is Surging Today - Nasdaq
nasdaq.com - May 14 at 11:53 PM
Financial Contrast: Incyte (NASDAQ:INCY) & iSpecimen (NASDAQ:ISPC)Financial Contrast: Incyte (NASDAQ:INCY) & iSpecimen (NASDAQ:ISPC)
americanbankingnews.com - May 14 at 2:18 AM
Pharma Stock Roundup: PFEs Biohaven Buyout Offer, BAYRYs Q1 Earnings Update - NasdaqPharma Stock Roundup: PFE's Biohaven Buyout Offer, BAYRY's Q1 Earnings Update - Nasdaq
nasdaq.com - May 13 at 4:40 PM
Mizuho Sees Relief For This Small-Cap Stock After Patent Legal Overhang LiftedMizuho Sees Relief For This Small-Cap Stock After Patent Legal Overhang Lifted
benzinga.com - May 13 at 2:32 PM
Melanoma Cancer Market Size And Forecast | AB Sciences, Incyte, Merck, Novartis, Pierre Fabre, Amgen, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo – Queen Anne and Mangolia News - Queen Anne and Mangolia NewsMelanoma Cancer Market Size And Forecast | AB Sciences, Incyte, Merck, Novartis, Pierre Fabre, Amgen, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo – Queen Anne and Mangolia News - Queen Anne and Mangolia News
magnolianews.net - May 13 at 3:06 AM
FDA Approves Lilly and Incytes OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19 | Eli Lilly and Company - Eli LillyFDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19 | Eli Lilly and Company - Eli Lilly
investor.lilly.com - May 13 at 3:06 AM
Recent Research on Bromodomain Testis Specific Protein Market Shows After Pendamic Future for Key player and Industry Growth, Forecast Till 2028: F. Hoffmann-La Roche Ltd, Forma Therapeutics Inc, Incyte Corp – Queen Anne and Mangolia News - Queen Anne and Mangolia NewsRecent Research on Bromodomain Testis Specific Protein Market Shows After Pendamic Future for Key player and Industry Growth, Forecast Till 2028: F. Hoffmann-La Roche Ltd, Forma Therapeutics Inc, Incyte Corp – Queen Anne and Mangolia News - Queen Anne and Mangolia News
magnolianews.net - May 12 at 9:37 AM
Immune Checkpoint Inhibitors Market Size 2022 Analysis by 2029 | Key Players – Bristol Myer Squibb, AstraZeneca, Merck & Co., Roche / Genentech, Incyte Corporation – Queen Anne and Mangolia News - Queen Anne and Mangolia NewsImmune Checkpoint Inhibitors Market Size 2022 Analysis by 2029 | Key Players – Bristol Myer Squibb, AstraZeneca, Merck & Co., Roche / Genentech, Incyte Corporation – Queen Anne and Mangolia News - Queen Anne and Mangolia News
magnolianews.net - May 12 at 9:37 AM
FDA grants approval for Lilly-Incytes Covid-19 treatment - Pharmaceutical TechnologyFDA grants approval for Lilly-Incyte's Covid-19 treatment - Pharmaceutical Technology
pharmaceutical-technology.com - May 12 at 9:37 AM
Lillys (LLY) Olumiant Gets Full Approval From FDA for COVIDLilly's (LLY) Olumiant Gets Full Approval From FDA for COVID
finance.yahoo.com - May 12 at 9:37 AM
Vitiligo Drug Market to Witness Growth Acceleration | AXIM Biotechnologies, Incyte Corporation, Dermavant Sciences – Queen Anne and Mangolia News - Queen Anne and Mangolia NewsVitiligo Drug Market to Witness Growth Acceleration | AXIM Biotechnologies, Incyte Corporation, Dermavant Sciences – Queen Anne and Mangolia News - Queen Anne and Mangolia News
magnolianews.net - May 12 at 12:35 AM
Teva faces $100M lawsuit from Israel over unpaid Copaxone royalties: report - FiercePharmaTeva faces $100M lawsuit from Israel over unpaid Copaxone royalties: report - FiercePharma
fiercepharma.com - May 11 at 2:34 PM
Eli Lilly & Co. (LLY) and Incyte (INCY) Announce FDA Approval of OLUMIANT for Treatment of Certain Hospitalized Patients with COVID-19 - StreetInsider.comEli Lilly & Co. (LLY) and Incyte (INCY) Announce FDA Approval of OLUMIANT for Treatment of Certain Hospitalized Patients with COVID-19 - StreetInsider.com
streetinsider.com - May 11 at 2:34 PM
Bristol-Myers taps Utah Jazz player for cardiomyopathy awareness push - FiercePharmaBristol-Myers taps Utah Jazz player for cardiomyopathy awareness push - FiercePharma
fiercepharma.com - May 11 at 9:33 AM
FDA approves Eli Lilly and Incytes Olumiant for treatment of certain hospitalized adults with COVID-19 - MarketWatchFDA approves Eli Lilly and Incyte's Olumiant for treatment of certain hospitalized adults with COVID-19 - MarketWatch
marketwatch.com - May 11 at 9:33 AM
FDA Approves Lilly, Incyte Drug Olumiant for Certain Hospitalized Covid Patients - MarketWatchFDA Approves Lilly, Incyte Drug Olumiant for Certain Hospitalized Covid Patients - MarketWatch
marketwatch.com - May 11 at 9:33 AM
FDA Approves Lilly and Incytes OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19
finance.yahoo.com - May 11 at 9:33 AM
FDA approves Eli Lilly and Incytes Olumiant for treatment of certain hospitalized adults with COVID-19FDA approves Eli Lilly and Incyte's Olumiant for treatment of certain hospitalized adults with COVID-19
finance.yahoo.com - May 11 at 9:33 AM
FDA Approves Lilly and Incytes OLUMIANT (baricitinib) for Hospitalized Patients with COVID-19FDA Approves Lilly and Incyte's OLUMIANT (baricitinib) for Hospitalized Patients with COVID-19
benzinga.com - May 11 at 8:55 AM
Tyrosine Kinase JAK Inhibitors Consumption Market Outlook 2022-2030| Key Players – Pfizer, Incyte, Novartis, Eli Lilly – Queen Anne and Mangolia News - Queen Anne and Mangolia NewsTyrosine Kinase JAK Inhibitors Consumption Market Outlook 2022-2030| Key Players – Pfizer, Incyte, Novartis, Eli Lilly – Queen Anne and Mangolia News - Queen Anne and Mangolia News
magnolianews.net - May 10 at 9:48 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.